Active Ingredient History
Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. Milrinone is indicated for the treatment of congestive heart failure. Milrinone was marketed under the brand name Primacor. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Heart Failure (approved 2002)
Acute Coronary Syndrome (Phase 4)
Anesthesia (Phase 4)
Cardiac Output (Phase 2)
Cardiac Output, Low (Phase 4)
Cardiac Surgical Procedures (Phase 3)
Cardiomyopathies (Phase 4)
Cardio-Renal Syndrome (Phase 2)
Coronary Artery Disease (Phase 2)
Coronary Vasospasm (Phase 3)
Drugs, Investigational (Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Heart Defects, Congenital (Phase 2)
Heart Diseases (Phase 1)
Heart Failure (Phase 2)
Heart Transplantation (Phase 2)
Heart Valve Diseases (Phase 2)
Hemodynamics (Phase 4)
Hernias, Diaphragmatic, Congenital (Phase 2)
Hypertension, Pulmonary (Phase 4)
Infant (Phase 3)
Lung Diseases (Phase 2)
Milrinone (Phase 2)
Mitral Valve Insufficiency (Phase 3)
Myocardial Reperfusion Injury (Phase 1/Phase 2)
Pulmonary Edema (Phase 4)
Renal Insufficiency (Phase 2)
Respiratory Insufficiency (Phase 2)
Shock, Cardiogenic (Phase 4)
Shock, Septic (Phase 4)
Subarachnoid Hemorrhage (Phase 2)
Traumatology (Phase 2)
Vasospasm, Intracranial (Phase 2)
Ventricular Dysfunction, Right (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
